Entering text into the input field will update the search result below

Vical secures six patents covering HSV-2 vaccines

  • The USPTO issues six patents to Vical (VICL) covering its DNA vaccines for herpes simplex virus type 2 (HSV-2) containing specific gene sequences and formulated with its Vaxfectin adjuvant. The IP is jointly owned by the company and the University of Washington.
  • The patents cover composition of matter of plasmid DNA vaccines encoding several HSV-2 antigens, including envelope and tegument viral proteins, separately or in combination, and formulated with the Vaxfectin adjuvant.
  • The new patents add to Vical's patent estate that is based on its discovery that administering genetic sequences without the use of viral vectors will result in expression of the proteins encoded by the sequences.

Recommended For You

About FRTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
FRTX--
Fresh Tracks Therapeutics, Inc.